What You Should Know:
– OneCell Diagnostics, a genomics-based precision oncology company, announced today that it has raised $16M in an oversubscribed Series A funding round led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
– The funding will be used to advance its vision of democratizing precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable. Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will join the OneCell board of directors.
OneCell Diagnostics: Revolutionizing Precision Oncology with Genomic Innovations
OneCell Diagnostics is a pioneering precision oncology company specializing in genomics-based solutions to enhance cancer management. Its proprietary platform combines next-generation sequencing with advanced bioinformatics, artificial intelligence (AI), machine learning (ML), and multi-omics biomarker analysis to deliver cutting-edge cancer diagnostics.
- Liquid Biopsy Technology:
OneCell’s groundbreaking True-Single-Cell-Multi-omics platform drives its precision oncology diagnostics. The technology integrates Circulating Tumor Cell (CTC) DNA, CTC RNA, and cell surface protein testing from a single blood draw, representing a significant advancement over conventional liquid biopsy methods. Applications include:- Cancer screening.
- Monitoring treatment response.
- Detecting disease progression and recurrence.
- Flagship Product:
With Series A funding, OneCell is launching its next-generation liquid biopsy test, OncoIndx Ikon, in the U.S. market. This test detects and analyzes CTCs, providing actionable biomarkers that enhance diagnosis and treatment strategies for cancer patients. - Global Impact and Reach:
Operating from Silicon Valley and India, OneCell has already tested nearly 10,000 patients in India, showcasing the scalability, safety, and cost-effectiveness of its technology in clinical and laboratory settings. - Collaborations and Partnerships:
Strategic partnerships with leading institutions like Harvard Medical School and Stanford University bolster OneCell’s technological advancements and clinical applications. - Addressing a Global Challenge:
According to the World Health Organization, cancer impacts 20 million new patients annually, with 53.5 million living within five years of diagnosis. As cancer is driven by constant molecular-level changes, biomarker testing is critical. Over half of global oncology clinical trials now integrate biomarker testing to refine treatment decisions and monitor disease response during therapy.
By leveraging cutting-edge genomics and multi-omics technologies, OneCell Diagnostics is transforming the landscape of cancer diagnostics and precision oncology worldwide.
“We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,” said Mohan Uttarwar, CEO and Co-founder at OneCell Diagnostics. “By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalized cancer care worldwide.”
